Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment

Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of advanced melanoma, but many patients do not respond to ICIs alone, and thus there is need for additional treatment options. Topical immunomodulators such as diphencyprone (DPCP) also have clinical use in advanced melanoma, particularly in the treatment of cutaneous metastases. In a previous report, we characterized the enhanced clinical response to dual agent immunotherapy with pembrolizumab and DPCP in a patient with cutaneous melanoma metastases. To improve mechanistic understanding of this response, we analyzed proteomic data using the Olink immuno-oncology panel of 96 biomarkers from tissue and serum samples of this patient throughout his treatment course. Particular attention was paid to programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and lymphocyte-activation gene 3 (LAG-3) given they are all targeted by ICIs in clinical practice. These proteins were upregulated during the period of DPCP monotherapy, then downregulated during pembrolizumab monotherapy, and then robustly upregulated again during dual therapy. Although not exclusively, the induction of checkpoint inhibitor proteins in the presence of DPCP suggests potential synergy between this agent and ICIs in the treatment of cutaneous melanoma metastases. Large-scale investigation is warranted to further evaluate this potential novel combination therapeutic approach.

Automated summary

Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized the treatment of advanced melanoma. However, many patients do not respond to ICIs alone, creating a need for additional treatment options. Diphencyprone (DPCP), a topical immunomodulator, has shown clinical use in the treatment of advanced melanoma, particularly in cutaneous metastases. In this study, the authors analyzed proteomic data from a patient treated with pembrolizumab and DPCP, and observed upregulation of checkpoint inhibitor proteins during DPCP monotherapy, downregulation during pembrolizumab monotherapy, and robust upregulation during dual therapy. This suggests potential synergy between DPCP and ICIs in the treatment of cutaneous melanoma metastases.